Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

HOUSTON and LAKE FOREST, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”) and Genomic Testing Cooperative, LCA (“GTC”) today announced a collaboration to integrate GTC’s next-generation sequencing (NGS) technology into the CNSide^® cerebrospinal fluid (CSF) assay platform. The collaboration is expected to enable comprehensive DNA and RNA profiling across hundreds of clinically relevant biomarkers from a single CSF specimen, extending CNSide from guideline-recognized CTC enumeration into the guideline-recognized DNA and tumor-derived DNA analytic layer within one integrated platform. The collaboration advances Plus’ three-pillar CNS oncology strategy: targeted radiotherapeutics led by REYOBIQ^™ (rhenium Re186 obisbemeda); precision diagnostics anchored by the CNSide CSF platform; and AI-enabled data analytics through the Company’s strategic partnership with Ephemeral Technologies.